There has been a fairly big effort over the last couple of years to look at how we can build on our strengths on the research side when it comes to vaccines, where we have very strong capabilities to make sure that we can produce vaccines at scale.
If you look at what the government did in the last budget to invest in a biomanufacturing and life sciences strategy for Canada, it tries to amplify what we've been able to do on the research side, which has been critical to the development of things like mRNA vaccines, but coupled with more strength with respect to our capabilities on the downstream side in terms of having the production facilities at scale, having the talent pipeline you need to make sure that you can actually support these facilities. You've seen a number of efforts to build on what's here, to make sure we can be better prepared for future pandemics.
The reality is that in the middle of an emergency you are looking for supply to make sure that your public is safe, so the focus there was to procure vaccines as quickly as possible from wherever they were produced. However, over the long run, I think there's a real effort being made to try to make sure we actually have the capacity at all steps of the supply chain that we need, to make sure we can produce vaccines at scale here in Canada.